Feasibility of Adipose Tissue Triglyceride (TG) Labelling in Familial Partial Lipodystrophy (FPLD)

Exclusion Criteria

• •An individual who meets any of the following criteria will be excluded from participation in this study:
• •1. Uncontrolled diabetes, defined as HbA1C \>8% at screening.
• •2. Use of insulin secretagogues (sulfonylureas) in week prior to Study Visit 1.
• •3. Changes in insulin dose \>30% of total daily dose in the 2 weeks prior to Study Visit 1.
• •4. Use of niacin in the week prior to Study Visit 1.
• •5. Use of antiplatelets that cannot be safely held for the appropriate duration prior to each biopsy visit, including Plavix (one week prior to biopsy), aspirin (one week prior to biopsy) and NSAIDS (48 hours prior to biopsy).
• •6. Chronic use of anticoagulant medications that cannot be safely stopped for an appropriate duration of time prior to a biopsy procedure.
• •7. Lipemia defined as non-fasting triglycerides of \>1000 mg/dL at screening.
• •8. Renal dysfunction defined as GFR \<60 mL/min/1.73 m\^2 at screening.
• •9. Consuming extreme macronutrient diet (e.g., very low-carbohydrate, high fat diets such as ketogenic, paleo or Atkins diets, among others).
• •10. Positive pregnancy test or breastfeeding at screening.
• •11. History of HIV, hepatitis B or C infection.
• •12. History of acquired lipodystrophy.
• •13. Clinically significant abnormalities in thyroid function, liver function, blood counts, or blood minerals as assessed by screening labs.
• •14. Inability to comply with planned study procedures.
• •15. Inability of subject to understand and the willingness to sign a written informed consent document.
• •16. Any condition which in the opinion of the investigator increases risk to subjects, prevents subject from complying with study procedures, prevents the subject from completing the study, or interferes with the interpretation of study results.